312
Participants
Start Date
January 29, 2021
Primary Completion Date
April 18, 2022
Study Completion Date
October 19, 2022
Inclisiran sodium
Subcutaneously injected on Day 1, 90 and 270.
Placebo
Subcutaneously injected on Day 1, 90, and 270.
Novartis Investigative Site, Nagoya
Novartis Investigative Site, Chiyoda City
Novartis Investigative Site, Matsudo
Novartis Investigative Site, Itoshima
Novartis Investigative Site, Kitakyushu
Novartis Investigative Site, Kitakyushu
Novartis Investigative Site, Kitakyushu
Novartis Investigative Site, Kitakyushu
Novartis Investigative Site, Nakagawa
Novartis Investigative Site, Sapporo
Novartis Investigative Site, Sapporo
Novartis Investigative Site, Sashima-gun
Novartis Investigative Site, Tsuchiura
Novartis Investigative Site, Kahoku-gun
Novartis Investigative Site, Kanazawa
Novartis Investigative Site, Kanazawa
Novartis Investigative Site, Komatsu
Novartis Investigative Site, Takamatsu
Novartis Investigative Site, Fujisawa
Novartis Investigative Site, Kawasaki
Novartis Investigative Site, Kuse
Novartis Investigative Site, Sendai
Novartis Investigative Site, Ōmura
Novartis Investigative Site, Izumisano
Novartis Investigative Site, Matsubara
Novartis Investigative Site, Osaka
Novartis Investigative Site, Osaka
Novartis Investigative Site, Osaka
Novartis Investigative Site, Suita
Novartis Investigative Site, Suita
Novartis Investigative Site, Iruma-gun
Novartis Investigative Site, Sayama
Novartis Investigative Site, Chuo-ku
Novartis Investigative Site, Chuo-ku
Novartis Investigative Site, Nerima-ku
Novartis Investigative Site, Shinagawa-ku
Novartis Investigative Site, Shinjuku Ku
Novartis Investigative Site, Chuoh-ku
Novartis Investigative Site, Gifu
Novartis Investigative Site, Kyoto
Novartis Investigative Site, Ōita
Novartis Investigative Site, Saga
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY